Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC Form 6-K March 23, 2017
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 23 March 2017
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
In dicate has already mode sub-other the maniety and files on
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

Yes No x

GlaxoSmithKline plc (the 'Company')

Securities Exchange Act of 1934.

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Dr K Slaoui

b) Position/status

PCA of Dr M M Slaoui
(Chairman, Global Vaccines)

c) Initial notification / amendment Initial notification

Details of the issuer, emission allowance market participant, auction

platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of

3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

American Depositary Shares

('ADSs')

a) Description of the financial instrument

ISIN: US37733W1053 An increase of 4 ADSs following the notional allocation of ADSs on 22 March 2017, at a price of \$42.28 per ADS, as a result

b) Nature of the transaction \$42.28 per ADS, as a result of the revaluation of the cash

element of the notional investment held within the

GSK 401(K) plan.

Price(s) Volume(s)

c) Price(s) and volume(s)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

\$42.28 4

Aggregated information

d) Aggregated volume n/a (single transaction)

Price

e) Date of the transaction 2017-03-22

Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: March 23, 2017

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc